Giant axonal neuropathy–associated gigaxonin mutations impair intermediate filament protein degradation

Thumbnail Image
Mahammad, Saleemulla
Prasanna Murthy, S. N.
Didonna, Alessandro
Grin, Boris
Israeli, Eitan
Perrot, Rodolphe
Bomont, Pascale
Julien, Jean-Pierre
Kuczmarski, Edward
Opal, Puneet
Goldman, Robert D.
Alternative Title
Date Created
Related Materials
Replaced By
Giant axonal neuropathy (GAN) is an early-onset neurological disorder caused by mutations in the GAN gene (encoding for gigaxonin), which is predicted to be an E3 ligase adaptor. In GAN, aggregates of intermediate filaments (IFs) represent the main pathological feature detected in neurons and other cell types, including patients’ dermal fibroblasts. The molecular mechanism by which these mutations cause IFs to aggregate is unknown. Using fibroblasts from patients and normal individuals, as well as Gan–/– mice, we demonstrated that gigaxonin was responsible for the degradation of vimentin IFs. Gigaxonin was similarly involved in the degradation of peripherin and neurofilament IF proteins in neurons. Furthermore, proteasome inhibition by MG-132 reversed the clearance of IF proteins in cells overexpressing gigaxonin, demonstrating the involvement of the proteasomal degradation pathway. Together, these findings identify gigaxonin as a major factor in the degradation of cytoskeletal IFs and provide an explanation for IF aggregate accumulation, the subcellular hallmark of this devastating human disease.
Author Posting. © American Society for Clinical Investigation, 2013. This article is posted here by permission of American Society for Clinical Investigation for personal use, not for redistribution. The definitive version was published in Journal of Clinical Investigation 123 (2013): 1964–1975, doi:10.1172/JCI66387.
Embargo Date
Journal of Clinical Investigation 123 (2013): 1964–1975
Cruise ID
Cruise DOI
Vessel Name